Articles related to SMALL CELL LUNG CANCER (SCLC)

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

“The extended-hours model was effective… early morning dose, in-center observation, overnight remote monitoring equipment, and next-day follow-up cut the need for extended shifts and differential pay.”

“Second-line therapy should not be dismissed outright in platinum-refractory or early-relapsing disease. It remains a relevant part of comprehensive care.” — Tingting Tan, MD, PhD, City of Hope

Global phase 3 study randomized patients with platinum-refractory extensive-stage SCLC to first-in-class bispecific immunotherapy versus regional standard chemotherapy, achieving primary overall survival endpoint with consistent safety profile.

Durvalumab consolidation therapy demonstrated unprecedented survival benefit in limited-stage SCLC, extending median overall survival by nearly two years compared to placebo.

This review encompasses nine recent studies in oncology, highlighting the application of innovative therapies and drug combinations in the treatment of lung cancer.